Vaccines and Public Health
Adult immunization rates are falling short of national targets. Learn how global, federal, and state policies affect vaccination uptake. Leverage our findings to guide your strategies. Rely on our expertise commercializing novel and therapeutic vaccines.
Diagnostic Testing and Patient Screening Are Key to Successful US COVID-19 Response
As the novel coronavirus (COVID-19) spreads throughout the United States, media and policy focus on the rollout of diagnostic testing for the disease has greatly increased. Understanding the role of testing and screening is key to the control of this outbreak.
Considerations for Patient Support Programs in the COVID-19 Era
As the economic and social impact of COVID-19 change how patients access and receive care, manufacturers and third-party suppliers must consider how to evolve their patient support programs to meet the shifting access and affordability needs of patients.
Interview: E7 – Get the Facts on COVID-19: Post-Acute Care
Tune into the seventh episode of our series that focuses on COVID-19. In episode 7, Avalere experts from the Health Plans and Provider’s practice discuss the short- and long-term implications for post-acute care as a result of COVID-19.
Patients Using DMARDs for Autoimmune Diseases May Encounter Access Challenges
As COVID-19 deaths increase, the FDA is evaluating and considering approval of treatments more quickly, but the rush to find treatment options is creating new access considerations for patients and providers.
Considerations for the Role of Pharmacies and the Retail Pharmacy Business Model in Response to COVID-19
As COVID-19 continues to stress the US healthcare system, pharmacists and retail pharmacies may help respond to the pandemic.
Amid COVID-19 Pandemic, Influenza Disease Burden Remains Significant
Although influenza disease burden is high, vaccine uptake remains low.
Medicare Part D Plans Continue to Require Cost Sharing for Vaccines
An Avalere analysis finds that Medicare Part D plans allow $0 cost-sharing for select vaccines just 4% of the time, likely affecting immunization uptake.
Home Testing Can Keep People Safe and Get Them Back to Work—Here’s How
On April 7, Gillian Woollett authored a Health Affairs blog piece with Ge Bai from the Johns Hopkins Carey Business School and Bruce Pyenson from Milliman about the role that testing plays in recovering from the COVID-19 pandemic.
COVID-19: Future Considerations for Biopharma
As the COVID-19 pandemic unfolds, stakeholders across the healthcare system are facing new realities that will affect the environment in which drugs are commercialized and accessed.
Where We Stand on COVID-19 Treatments
Globally, the need to flatten the epidemic curve of COVID-19 cases has become the top public health priority to save lives and minimize the burden on the health care system. In the absence of treatments and prophylactics for the novel coronavirus, social distancing and quarantine strategies continue to be implemented in the US.
Webinar: The Impact of COVID-19 on the Health Insurance Industry
Our panel of experts engaged in an in-depth discussion of the rapidly evolving regulatory environment surrounding COVID-19 testing and treatment and the strategic, financial, and operational challenges this disease presents for health insurers.
Ensuring COVID-19 Vaccine Affordability
On March 30, Avalere policy experts published a piece in the Health Affairs blog about the existing programs in place to ensure patient access to affordable COVID-19 vaccines.
Recent History Shows Variability in Vaccine Development Timeline
Opportunities exist to accelerate potential vaccine development.
Interview: E3 – Get the Facts on COVID-19: A Comparison to Other Outbreaks
In the third episode of this series, Avalere experts discuss how the COVID-19 pandemic and response compares to previous outbreaks.
Diagnostic Considerations for COVID-19
As the Coronavirus Disease 2019 (COVID-19), caused by the novel SARS-CoV-2 virus, rapidly spreads through the US, media and public scrutiny over the current diagnostic testing landscape has increased, given that the US lags behind other countries in the number of tests performed and turnaround time for results reported.
Interview: E2 – Get the Facts on COVID-19: Patient Out-of-Pocket Costs
Tune into the second episode of our podcast series that focuses on COVID-19. In episode 2, Avalere experts discuss how Medicare, Medicaid, and commercial plans will address the patient out of pocket costs associated with COVID-19 testing and treatment. They also acknowledge how commercial manufacturers are addressing the shortage of tests and turnaround for COVID-19 testing in the US.
Interview: E1 – Get the Facts on COVID-19: Vaccination Affordability and Access
Tune in to hear the first episode of our podcast series that focuses on COVID-19. In this episode, Avalere experts will discuss COVID-19 vaccinations, focusing on the timeline of development, affordability, and access.
Preventive Care Commentary Featured in Health Affairs Blog
On January 29, Richard Hughes published a piece on the Health Affairs blog discussing the presidential candidates’ opportunities to incorporate preventative services into their healthcare policy platforms.
Avalere Commentary on the 2020 National Vaccine Plan Featured in Health Affairs Blog
On December 16, Avalere policy experts, including Senior Adviser Dr. Angela Shen, published a piece in Health Affairs blog entitled “Shaping the 2020 National Vaccine Plan.” It explores the progress to date against the 2010 National Vaccine Plan (NVP), recurring challenges, and the 2020 NVP.
Immunization Implications in CY 2020 MPFS Final Rule
Two decisions finalized in the CY 2020 Medicare Physician Fee Schedule (MPFS) rule have important implications for vaccine policy and access.